Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated1
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

terminated133%
withdrawn133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959
terminatednot_applicable

Adjuvant Radiation for High Risk Bladder Cancer

NCT01954173
withdrawnphase_2

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520

Clinical Trials (3)

Showing 3 of 3 trials
NCT02142959Phase 2

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

Completed
NCT01954173Not Applicable

Adjuvant Radiation for High Risk Bladder Cancer

Terminated
NCT02678520Phase 2

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3